<DOC>
	<DOCNO>NCT01027806</DOCNO>
	<brief_summary>The investigator lead hypothesis : - Oral therapy montelukast may lead improved sleep study finding child mild moderate Obstructive Sleep Apnea Syndrome ( OSAS ) require surgical removal adenoid tonsils OSAS . - A significant proportion child OSAS treat montelukast show reduced severity OSAS , remove need surgical intervention .</brief_summary>
	<brief_title>Effect Montelukast Therapy Obstructive Sleep Apnea ( OSA ) Children</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Eligible inclusion study symptomatic snore child &gt; 2 year age &lt; 10 year age , snore apnea hypopnea index ( AHI ) &gt; 2/hrTST ( hour total sleep time ) , T &amp; A therefore contemplate . Also among , include child refer evaluation snore history allergic rhinitis . Exclusion criterion include : Hypersensitivity montelukast , immunodeficiency immunosuppressant therapy , craniofacial , neuromuscular , syndromic define genetic abnormality , acute upper respiratory tract infection , systemic corticosteroid therapy antibiotic therapy 2 week previous study , child already adenotonsillectomy . In addition , child chronically receive oral antihistamine preparation nasal decongestant require continue use medication throughout duration study . Patients receive immunotherapy continue regimen without escalation dose frequency throughout duration study . In addition , patient severe OSA opinion treat physician require early surgical intervention OSA exclude eligibility study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Sleep</keyword>
	<keyword>Obstructive Sleep Apnea</keyword>
</DOC>